BR0311781A - Quinone-based therapeutic agent for liver disease - Google Patents

Quinone-based therapeutic agent for liver disease

Info

Publication number
BR0311781A
BR0311781A BR0311781-2A BR0311781A BR0311781A BR 0311781 A BR0311781 A BR 0311781A BR 0311781 A BR0311781 A BR 0311781A BR 0311781 A BR0311781 A BR 0311781A
Authority
BR
Brazil
Prior art keywords
liver disease
preventative
liver cancer
therapeutic agent
remedy
Prior art date
Application number
BR0311781-2A
Other languages
Portuguese (pt)
Inventor
Yukihiro Koike
Yasushi Shiratori
Shuichiro Shiina
Takuma Teratani
Shinpei Sato
Keisuke Hamamura
Masatoshi Akmatsu
Shuntaro Obi
Ryosuke Tateishi
Tomonori Fujishima
Miho Kanda
Haruhiko Yoshida
Takashi Ishikawa
Tateo Kawase
Masao Omata
Toshihiko Mizuta
Tsutomu Yasutake
Yuichiro Eguchi
Masaru Fujimoto
Iwata Ozaki
Ikuko Wada
Kyosuke Yamamoto
Original Assignee
Eisai Co Ltd
Yukihiro Koike
Yasushi Shiratori
Masao Omata
Toshihiko Mizuta
Kyosuke Yamamoto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2002204709A external-priority patent/JP2004067513A/en
Application filed by Eisai Co Ltd, Yukihiro Koike, Yasushi Shiratori, Masao Omata, Toshihiko Mizuta, Kyosuke Yamamoto filed Critical Eisai Co Ltd
Publication of BR0311781A publication Critical patent/BR0311781A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"AGENTE TERAPêUTICO A BASE DE QUINONA PARA HEPATOPATIA". Com vistas a proporcionar um medicamento para tratamento de uma doença do fígado, particularmente pela inibição da geração de invasão venosa portal (PVI), um remédio/preventivo para uma doença de fígado contendo menatetrenona como um ingrediente ativo é apresentado. Este remédio/preventivo para uma doença de fígado é eficaz conlra o câncer de fígado, em particular, câncer de fígado de DCP (des-<sym>-carboxi protrombina)-positiva. o remédio/preventivo acima descrito para uma doença de fígado contendo menatetrenona como ingrediente ativo exerce um efeito notável de melhorar a convalescença após o tratamento para câncer do fígado, exibindo, deste modo, um excelente efeito como um inibidor de recorrência de câncer de fígado."QUINONE BASED THERAPEUTIC AGENT FOR Hepatopathy". In order to provide a medicament for treating liver disease, particularly by inhibiting portal venous invasion (PVI) generation, a remedy / preventative for a liver disease containing menatetrenone as an active ingredient is presented. This remedy / preventative for a liver disease is effective against liver cancer, in particular, prothrombin-positive (DCP) liver cancer. The above-described remedy / preventative for a liver disease containing menatetrenone as an active ingredient has a remarkable effect on improving convalescence following treatment for liver cancer, thereby exhibiting an excellent effect as a liver cancer recurrence inhibitor.

BR0311781-2A 2002-06-12 2003-06-12 Quinone-based therapeutic agent for liver disease BR0311781A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2002172133 2002-06-12
JP2002172162 2002-06-13
JP2002204709A JP2004067513A (en) 2002-06-12 2002-07-12 Quinone-based therapeutic agent for hepatic disease
JP2002245178 2002-08-26
PCT/JP2002/009640 WO2003105818A1 (en) 2002-06-12 2002-09-19 Quinone-based remedies for liver diseases
PCT/JP2003/007491 WO2003105819A1 (en) 2002-06-12 2003-06-12 Quinone-type remedy for liver disease

Publications (1)

Publication Number Publication Date
BR0311781A true BR0311781A (en) 2005-04-12

Family

ID=29741087

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0311781-2A BR0311781A (en) 2002-06-12 2003-06-12 Quinone-based therapeutic agent for liver disease

Country Status (4)

Country Link
AU (1) AU2003277184B2 (en)
BR (1) BR0311781A (en)
CA (1) CA2488880A1 (en)
WO (1) WO2003105819A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060111666A (en) * 2004-01-06 2006-10-27 에자이 가부시키가이샤 Preventive for the onset of liver cancer comprising quinone compound as the active ingredient
WO2005077351A1 (en) * 2004-02-12 2005-08-25 Eisai Co., Ltd Quinone remedies for lung diseases
JP5103608B2 (en) * 2006-02-10 2012-12-19 国立大学法人名古屋大学 Pharmaceutical composition for treatment or prevention of liver cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63185921A (en) * 1987-01-28 1988-08-01 Takeda Chem Ind Ltd Remedy for hepatic disease

Also Published As

Publication number Publication date
CA2488880A1 (en) 2003-12-24
WO2003105819A1 (en) 2003-12-24
AU2003277184A1 (en) 2003-12-31
AU2003277184B2 (en) 2007-11-01

Similar Documents

Publication Publication Date Title
CY1116463T1 (en) Combination therapy for the therapeutic treatment of Protein Deficiency Disorders
AR027355A1 (en) THIAZOLIDINCARBOXILIC ACIDS
GT200300245A (en) COMBINED ADMINISTRATION OF AN INDOLINONE WITH A CHEMOTHERAPEUTIC AGENT FOR CELL PROLIFERATION DISORDERS
AR044007A1 (en) METHODS FOR THE TREATMENT OF PARKINSON&#39;S DISEASE
ECSP003610A (en) PYRIMIDINE-2,4,6 METALOPROTEIN INHIBITING TRIONES
AR051405A1 (en) 2-CARBOXAMIDE (3-AMINO) THIOPHENE COMPOUNDS
WO2005044181A3 (en) Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
BRPI0417072A (en) preventive agent for vasculitis
HK1079519A1 (en) Furyl compounds
CU20070203A7 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES A DIFFENILUREA REPLACED WITH OMEGA-CARBOXIARIL FOR THE TREATMENT OF CANCER
BR0208563A (en) n-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
BR0209127A (en) compounds, pharmaceutical compositions, methods for treating pain, methods for modulating a pharmacological response and uses of compounds
BRPI0507895A (en) composition for the treatment of chronic venous insufficiency, comprising an extract of red vine leaves and an anti-inflammatory agent
BR0311460A (en) Modified release pharmaceutical composition, use of a formulation, and method for treating a cardiovascular disorder in a patient
NO20071426L (en) Cancer combination therapy including AZD2171 and Imatinib
MX2007004955A (en) Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally.
ATE477256T1 (en) THIENYL COMPOUNDS
UY27872A1 (en) CASPASA INHIBITORS AND USES OF THE SAME.
MXPA05004697A (en) Pharmaceutical solutions comprising a modafinil compound and their use for the manufacture of a medicament for treating different diseases.
NO20033665D0 (en) Azoles as malonyl-CoA decarboxylase inhibitors useful as metabolic modulators
WO2005065074A3 (en) Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
CR20230052A (en) Combinations for the treatment of cancer.
BR0311781A (en) Quinone-based therapeutic agent for liver disease
AR062779A1 (en) TREATMENT OF MULTIPLE SCLEROSIS (MS)
AR026911A1 (en) PHARMACEUTICAL PREPARATION FOR THE TREATMENT OF TUMOR AFFECTIONS

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: YUKIHIRO KOIKE (JP) , YASUSHI SHIRATORI (JP) , MAS

Free format text: TRANSFERIDO DE: EISAI CO., LTD.

B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE 7A. E 8A. ANUIDADE(S).

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE AS 7A E 8A ANUIDADES.